IOF and IFCC review calls for harmonization of assays for reference bone turnover markers
New review describes the current status of assays for PINP and β-CTX in blood, as well as the plans for and progress towards the achievement of harmonization or standardization of commercial assays for these reference markers
Published 2021-01-15 · Original archive entry · Explore research explainers
Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence.
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays [1].
The newly published review ' END
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays [1].
The newly published review ' END